BioSpace News Archive

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 11:15 a.m. (EST).

Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it will present at the upcoming WORLDSymposium 2024 Conference, held in San Diego, February 4-9, 2024.

Arrivo BioVentures proudly announces the appointment of Dr. Joel Raskin as its Chief Medical Advisor.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 8-11, 2024.

Quadrant Biosciences has reached a new milestone in their quest to provide integrated solutions to families who, for decades, have been navigating a very fractured health system surrounding autism services.

Legend Biotech Corporation closed its previously announced exclusive, worldwide license agreement with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell cell therapies targeting Delta-like ligand protein 3, including Legend Biotech’s existing autologous CAR-T cell therapy candidate, LB2102.1 Under the terms of the license agreement closed , Legend Biotech will receive a $100 million upfront cash payment.

Assertio Holdings, Inc., a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, announced that Dan Peisert is stepping down as the Company’s Chief Executive Officer.

Cardio Diagnostics Holdings, Inc. announced that the American Medical Association has granted and assigned a dedicated Current Procedural Terminology Proprietary Laboratory Analysis code, 0439U, for the company’s AI-driven coronary heart disease event risk assessment test, Epi+Gen CHD.